{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T15:11:29Z","timestamp":1776525089471,"version":"3.51.2"},"publisher-location":"Cham","reference-count":58,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319596587","type":"print"},{"value":"9783319596594","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/164_2017_28","type":"book-chapter","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T05:34:01Z","timestamp":1492752841000},"page":"307-328","source":"Crossref","is-referenced-by-count":9,"title":["Vasopressin and Vasopressin Antagonists in Heart Failure"],"prefix":"10.1007","author":[{"given":"Julie K.","family":"Vishram-Nielsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,22]]},"reference":[{"key":"28_CR1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/eurjhf\/hfq226","volume":"13","author":"D Aronson","year":"2011","unstructured":"Aronson D, Verbalis JG, Mueller M et al (2011) Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur J Heart Fail 13:327\u2013336","journal-title":"Eur J Heart Fail"},{"key":"28_CR2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/bs.acc.2015.10.006","volume":"73","author":"L Balling","year":"2016","unstructured":"Balling L, Gustafsson F (2016) Copeptin in heart failure. Adv Clin Chem 73:29\u201364","journal-title":"Adv Clin Chem"},{"key":"28_CR3","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/eurjhf\/hfr086","volume":"13","author":"L Balling","year":"2011","unstructured":"Balling L, Schou M, Videbaek L et al (2011) Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure. Eur J Heart Fail 13:968\u2013973","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"28_CR4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cardfail.2012.01.019","volume":"18","author":"L Balling","year":"2012","unstructured":"Balling L, Kistorp C, Schou M et al (2012) Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail 18(5):351\u2013358","journal-title":"J Card Fail"},{"key":"28_CR5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10741-010-9193-3","volume":"17","author":"L Bettari","year":"2012","unstructured":"Bettari L, Fiuzat M, Felker GM et al (2012) Significance of hyponatremia in heart failure. Heart Fail Rev 17:17\u201326","journal-title":"Heart Fail Rev"},{"issue":"9146","key":"28_CR6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II","year":"1999","unstructured":"CIBIS-II (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. CIBIS-II Investigators and Committees. Lancet 353(9146):9\u201313","journal-title":"Lancet"},{"key":"28_CR7","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.100.12.1311","volume":"100","author":"HA Cooper","year":"1999","unstructured":"Cooper HA, Dries DL, Davis CE et al (1999) Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100:1311\u20131315","journal-title":"Circulation"},{"key":"28_CR8","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0735-1097(86)80333-3","volume":"7","author":"MA Creager","year":"1986","unstructured":"Creager MA, Faxon DP, Cutler SS et al (1986) Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 7:758\u2013765","journal-title":"J Am Coll Cardiol"},{"key":"28_CR9","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(08)60695-9","volume":"371","author":"G Decaux","year":"2008","unstructured":"Decaux G, Soupart A, Vassart G (2008) Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371:1624\u20131632","journal-title":"Lancet"},{"key":"28_CR10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","volume":"42","author":"M Domanski","year":"2003","unstructured":"Domanski M, Norman J, Pitt B et al (2003) Diuretic use, progressive heart failure and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 42:705\u2013708","journal-title":"J Am Coll Cardiol"},{"key":"28_CR11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cardfail.2009.12.021","volume":"16","author":"JK Ghali","year":"2010","unstructured":"Ghali JK, Tam SW (2010) The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Card Fail 16:419\u2013431","journal-title":"J Card Fail"},{"key":"28_CR12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/eurjhf\/hfs051","volume":"14","author":"JK Ghali","year":"2012","unstructured":"Ghali JK, Orlandi C, Abraham WT (2012) The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multi-centre, randomized, double-blind, placebo-controlled, parallel-group study. Eur J Heart Fail 14:642\u2013651","journal-title":"Eur J Heart Fail"},{"key":"28_CR13","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Gattis WA, O\u2019Conner CM et al (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291:1963\u20131971","journal-title":"JAMA"},{"key":"28_CR14","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr et al (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 297:1332\u20131343","journal-title":"JAMA"},{"key":"28_CR15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.22293","volume":"48","author":"P Gines","year":"2008","unstructured":"Gines P, Wong F, Watson H et al (2008) Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia. A randomized trial. Hepatology 48:204\u2013213","journal-title":"Hepatology"},{"key":"28_CR16","first-page":"389","volume-title":"Vasopressin: cellular and integrative functions","author":"SR Goldsmith","year":"1988","unstructured":"Goldsmith SR (1988) Baroreflex control of vasopressin secretion in normal humans. In: Cowley AW, Liard J-F, Ausiello DA (eds) Vasopressin: cellular and integrative functions. Raven Press, New York, pp 389\u2013397"},{"key":"28_CR17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/0735-1097(92)90321-D","volume":"19","author":"SR Goldsmith","year":"1992","unstructured":"Goldsmith SR (1992) Baroreflex loading maneuvers do not suppress increased plasma arginine vasopressin in patients with congestive heart failure. J Am Coll Cardiol 19:1180\u20131184","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"28_CR18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cardfail.2013.04.003","volume":"19","author":"SR Goldsmith","year":"2013","unstructured":"Goldsmith SR (2013) Hyponatremia in heart failure: time for a trial. J Card Fail 19(6):398\u2013400","journal-title":"J Card Fail"},{"key":"28_CR19","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2005.02.095","volume":"46","author":"SR Goldsmith","year":"2005","unstructured":"Goldsmith SR, Gheorghiade M (2005) Vasopressin antagonism in heart failure. J Am Coll Cardiol 46:1785\u20131791","journal-title":"J Am Coll Cardiol"},{"key":"28_CR20","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","volume":"1","author":"SR Goldsmith","year":"1983","unstructured":"Goldsmith SR, Francis GS, Cowley AW et al (1983) Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1:1385\u20131390","journal-title":"J Am Coll Cardiol"},{"key":"28_CR21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0735-1097(86)80417-X","volume":"8","author":"SR Goldsmith","year":"1986","unstructured":"Goldsmith SR, Francis GS, Cowley AW et al (1986) Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 8:779\u2013783","journal-title":"J Am Coll Cardiol"},{"key":"28_CR22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00000441-198911000-00003","volume":"298","author":"SR Goldsmith","year":"1989","unstructured":"Goldsmith SR, Dodge D, Cowley AW (1989) The effect of moderate hypotension on arginine vasopressin levels in normal humans. Am J Med Sci 298:295\u2013298","journal-title":"Am J Med Sci"},{"key":"28_CR23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cardfail.2008.06.003","volume":"14","author":"SR Goldsmith","year":"2008","unstructured":"Goldsmith SR, Elkayam U, Haught H et al (2008) Efficacy and safety of the vasopressin V1A\/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 14:641\u2013647","journal-title":"J Card Fail"},{"key":"28_CR24","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.cardfail.2011.08.012","volume":"17","author":"SR Goldsmith","year":"2011","unstructured":"Goldsmith SR, Gilbertson DT, Mackedanz SA et al (2011) Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Card Fail 17:982\u2013989","journal-title":"J Card Fail"},{"key":"28_CR25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","volume":"19","author":"PJ Hauptman","year":"2013","unstructured":"Hauptman PJ, Burnett J, Gheorghiade M et al (2013) Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 19:390\u2013397","journal-title":"J Card Fail"},{"key":"28_CR26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(24)35289-9","volume":"292","author":"T Hirano","year":"2000","unstructured":"Hirano T, Yamamura Y, Nakamura S et al (2000) Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292:288\u2013294","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"28_CR27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/cc2337","volume":"7","author":"CL Holmes","year":"2003","unstructured":"Holmes CL, Landry DW, Granton JT (2003) Science review: vasopressin and the cardiovascular system part 1 \u2013 receptor physiology. Crit Care 7(6):427\u2013434","journal-title":"Crit Care"},{"key":"28_CR28","first-page":"771","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"EK Jackson","year":"2006","unstructured":"Jackson EK (2006) Vasopressin and other agents affecting the renal conservation of water. In: Brunton L, Lazo JS, Parker KL (eds) Goodman and Gilman\u2019s the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 771\u2013778","edition":"11th"},{"key":"28_CR29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ki.2012.402","volume":"83","author":"AJ Jovanovich","year":"2013","unstructured":"Jovanovich AJ, Berl T (2013) Whereas vaptans do and do not fit in the treatment of hyponatremia. Kidney Int 83:563\u2013567","journal-title":"Kidney Int"},{"key":"28_CR30","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr et al (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297:1319\u20131331","journal-title":"JAMA"},{"key":"28_CR31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCHEARTFAILURE.112.970012","volume":"6","author":"D Lanfeur","year":"2013","unstructured":"Lanfeur D, Sabbah HN, Goldsmith SR et al (2013) Association of arginine vasopressin levels with outcomes and the effect of V2 blockage in patients hospitalized for heart failure with reduced ejection fraction. Insights from the EVEREST trial. Circ Heart Fail 6:47\u201352","journal-title":"Circ Heart Fail"},{"key":"28_CR32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1210\/jcem-59-5-924","volume":"59","author":"LS Lilly","year":"1984","unstructured":"Lilly LS, Dzau VJ, Williams GH et al (1984) Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J Clin Endocrinol Metab 59:924\u2013930","journal-title":"J Clin Endocrinol Metab"},{"key":"28_CR33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Dahlstr\u00f6m U, Filippatos G et al (2013) EUR observational research programme: regional differences and 1-year follow-up results of the heart failure pilot survey (ESC-HF Pilot). Eur J Heart Fail 15:808\u2013817","journal-title":"Eur J Heart Fail"},{"key":"28_CR34","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.clinthera.2009.07.011","volume":"31","author":"ZL Mao","year":"2009","unstructured":"Mao ZL, Stalker D, Keirns J (2009) Pharmacokinetics of conivaptan hydrochloride, a vasopressin V1A\/V2-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther 31:1542\u20131550","journal-title":"Clin Ther"},{"issue":"11","key":"28_CR35","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004","journal-title":"N Engl J Med"},{"key":"28_CR36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MJT.0b013e3181f890ad","volume":"18","author":"T Mondritzki","year":"2011","unstructured":"Mondritzki T, Kolkhof P, Sabbah HN et al (2011) Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2\/V1a receptor blockage in a preclinical heart failure model. Am J Ther 18:31\u201337","journal-title":"Am J Ther"},{"issue":"1","key":"28_CR37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","volume":"52","author":"NG Morgenthaler","year":"2006","unstructured":"Morgenthaler NG, Struck J, Alonso C et al (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52(1):112\u2013119","journal-title":"Clin Chem"},{"key":"28_CR38","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","volume":"93","author":"A Mosterd","year":"2007","unstructured":"Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93:1137\u20131146","journal-title":"Heart"},{"key":"28_CR39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jacc.2008.03.050","volume":"52","author":"S Neuhold","year":"2008","unstructured":"Neuhold S, Huelsmann M, Strunk G et al (2008) Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 52:266\u2013272","journal-title":"J Am Coll Cardiol"},{"key":"28_CR40","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1172\/JCI116881","volume":"92","author":"A Ohnishi","year":"1993","unstructured":"Ohnishi A, Orita Y, Okahara R et al (1993) Potent aquaretic agent: a novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 92:2653\u20132659","journal-title":"J Clin Invest"},{"key":"28_CR41","first-page":"IV80","volume":"75","author":"M Packer","year":"1987","unstructured":"Packer M, Lee WH, Kessler PD et al (1987) Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 75:IV80\u2013IV92","journal-title":"Circulation"},{"key":"28_CR42","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/jc.2012-4082","volume":"98","author":"A Peri","year":"2013","unstructured":"Peri A (2013) Clinical review: the use of vaptans in clinical endocrinology. J Clin Endocrinol Metab 98:1321\u20131332","journal-title":"J Clin Endocrinol Metab"},{"key":"28_CR43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709\u2013717","journal-title":"N Engl J Med"},{"key":"28_CR44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.7326\/0003-4819-14-1-42","volume":"14","author":"FH Robinson","year":"1940","unstructured":"Robinson FH, Farr LE (1940) The relation between clinical edema and the excretion of an antidiuretic substance in the urine. Ann Intern Med 14:42","journal-title":"Ann Intern Med"},{"key":"28_CR45","first-page":"F321","volume":"236","author":"RW Schrier","year":"1979","unstructured":"Schrier RW, Berl T, Anderson RJ (1979) Osmotic and nonosmotic control of vasopressin release. Am J Physiol 236:F321\u2013F332","journal-title":"Am J Physiol"},{"key":"28_CR46","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M et al (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355:2099\u20132112","journal-title":"N Engl J Med"},{"key":"28_CR47","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1172\/JCI119098","volume":"98","author":"C Serradeil-Le Gal","year":"1996","unstructured":"Serradeil-Le Gal C, Lacour C, Valette G et al (1996) Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 98:2729\u20132738","journal-title":"J Clin Invest"},{"issue":"5","key":"28_CR48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"SOLVD","year":"1991","unstructured":"SOLVD (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293\u2013302","journal-title":"N Engl J Med"},{"key":"28_CR49","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2362.2006.01724.x","volume":"36","author":"B Stoiser","year":"2006","unstructured":"Stoiser B, M\u00f6rtl D, H\u00fclsmann M et al (2006) Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 36:771\u2013778","journal-title":"Eur J Clin Invest"},{"key":"28_CR50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM198107303050506","volume":"305","author":"VL Szatalowicz","year":"1981","unstructured":"Szatalowicz VL, Arnold PE, Chaimovitz C et al (1981) Radio-immunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305:263\u2013266","journal-title":"N Engl J Med"},{"key":"28_CR51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-3565(24)36784-9","volume":"282","author":"A Tahara","year":"1997","unstructured":"Tahara A, Tomura Y, Wada K-I et al (1997) Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 282:301\u2013308","journal-title":"J Pharmacol Exp Ther"},{"key":"28_CR52","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","volume":"104","author":"JE Udelson","year":"2001","unstructured":"Udelson JE, Smith WB, Hendrix GH et al (2001) Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104:2417\u20132423","journal-title":"Circulation"},{"key":"28_CR53","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","volume":"49","author":"JE Udelson","year":"2007","unstructured":"Udelson JE, McGrew FA, Flores E et al (2007) Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49:2151\u20132159","journal-title":"J Am Coll Cardiol"},{"key":"28_CR54","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","volume":"52","author":"JE Udelson","year":"2008","unstructured":"Udelson JE, Orlandi C, Ouyang J et al (2008) Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction. J Am Coll Cardiol 52:1540\u20131545","journal-title":"J Am Coll Cardiol"},{"key":"28_CR55","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","volume":"17","author":"JE Udelson","year":"2011","unstructured":"Udelson JE, Bilsker M, Hauptman PJ et al (2011) A multi-center, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail 17:973\u2013981","journal-title":"J Card Fail"},{"key":"28_CR56","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.amjmed.2006.05.004","volume":"119","author":"JG Verbalis","year":"2006","unstructured":"Verbalis JG (2006) Whole-body volume regulation and escape from antidiuretics. Am J Med 119:S21\u2013S29","journal-title":"Am J Med"},{"key":"28_CR57","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S et al (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287:860\u2013867","journal-title":"J Pharmacol Exp Ther"},{"key":"28_CR58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1253\/jcj.32.745","volume":"32","author":"Y Yamane","year":"1968","unstructured":"Yamane Y (1968) Plasma ADH level in patients with chronic congestive heart failure. Jpn Circ J 32:745\u2013759","journal-title":"Jpn Circ J"}],"container-title":["Handbook of Experimental Pharmacology","Heart Failure"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2017_28","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T23:30:46Z","timestamp":1750203046000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2017_28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319596587","9783319596594"],"references-count":58,"URL":"https:\/\/doi.org\/10.1007\/164_2017_28","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}